Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385008 · ClinicalTrials.gov registry record · Phase 3
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT00385008 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 20 participants.
The verdict
NCT00385008, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
An evaluation of tablet disintegration and absorption and gastric transit of sumatriptan and naproxen sodium from a TREXIMA tablet and eletriptan from a RELPAX 40mg tablet.
Interventions
- DRUG Combination Product (sumatriptan succinate / naproxen sodium)
- DRUG RELPAX(eletriptan) 40mg Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-09-13 |
| Est. Completion | 2006-11-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00385008
The ClinicalTrials.gov registry entry for NCT00385008 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Combination Product (sumatriptan succinate / naproxen sodium) is the first listed.
NCT00385008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00385008 about?
NCT00385008 is a clinical study titled "TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine". An evaluation of tablet disintegration and absorption and gastric transit of sumatriptan and naproxen sodium from a TREXIMA tablet and eletriptan from a RELPAX 40mg tablet.
What is the current status of trial NCT00385008?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2006-09-13. Estimated completion is 2006-11-24.
What interventions are being tested in trial NCT00385008?
The interventions under investigation include: Combination Product (sumatriptan succinate / naproxen sodium) (DRUG), RELPAX(eletriptan) 40mg Tablet (DRUG).
Who is sponsoring clinical trial NCT00385008?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.